IN8bio has struck upon a ‘best-of-both-worlds’ approach using a subspecies of T cells expressing gamma-delta (γδ) T cell receptors (TCRs). The platform rests on the strength of significant ...
The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
Delhi, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: Global Gamma Delta T Cell Therapy Clinical ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
The Abingworth-backed biotech is developing therapies based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role in a host of immune responses and ...
GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies ...
Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...
Delhi, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: Download ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback